□ | □
□ □ | □
[] | □
The Choson ( or Yi ) dynasty , which was to rule until 1910 , built a new capital at Hanseong ( Seoul ) and established Confucianism as the official religion . The 1592 invasion by the Japanese shogun Hideyoshi was driven back by Choson and Ming forces , but only after six years of great devastation and suffering . The railroads have been extensively rebuilt , and in the South high-speed lines connect Seoul with Daegu and Busan in the southeast and Gwangju in the southwest . " But MedImmune contends that a federal law enacted in 1936 permits a party to take a contract dispute to court without having to break the agreement first . A lawyer for MedImmune Inc. asked the Supreme Court yesterday to let the company sue to overturn a patent owned by Genentech Inc. on a component of MedImmune 's blockbuster drug Synagis , even though MedImmune is paying royalties to use it.The U.S. Court of Appeals for the Federal Circuit , which has jurisdiction over patent law , blocked MedImmune from suing in 2004 , ruling that a 1998 deal that MedImmune agreed to with Genentech amounted to a recognition of its patent 's validity , leaving no genuine conflict for the courts to resolve . In 935 the Silla dynasty , which had been in decline for a century , was overthrown by Wang Kon , who had established ( 918 ) the Koryo dynasty ( the name was selected as an abbreviated form of Koguryo and is the source of the name Korea ) . In 1392 , Yi Songgye , a general who favored the Ming dynasty ( which had replaced the Mongols in China ) , seized the throne and established the Choson dynasty . " Genentech 's lawyer , Maureen E. Mahoney , reinforced that point in her argument , saying MedImmune is essentially seeking the right to back out of a deal that both sides made in good faith , and that " it has been settled [ law ] forever that . Still , the company reported a loss of $ 16.6 million in part because of poor sales of its inhaled flu vaccine , FluMist.Synagis is made with the use of an antibody synthesis technology on which Genentech holds a patent , known as the Cabilly II patent after the inventor Shmuel Cabilly.The patent runs through 2018 , though MedImmune says it is invalid and the U.S. Patent and Trademark Office is reviewing it.Because of a confidentiality agreement with Genentech , MedImmune does not disclose how much it pays in royalties on Synagis . " What we are presenting in this case is a dispute about money , " MedImmune 's lawyer , John G. Kester , told the court . This may explain a lot : Not only do cheaters apparently prosper , they get graduate degrees in business.That 's what business professor Donald L. McCabe of Rutgers University and his colleagues found when they surveyed more than 5,000 graduate students and asked if they had cheated in the past year - - and if so , how often .